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ControversialobservationshavebeenpublishedontheassociationofthecytotoxicTlymphocyteassociatedantigengene’svariants
with rheumatoid arthritis (RA). After genotyping 428 patients and 230 matched controls, the prevalence of the CT60
∗Ga l l e l ew a s
more frequent in RF- and/or anti-CCP-seropositive RApatients, compared to the healthy controls (P<. 001). Regression analysis
revealed that the CT60
∗G allele is a possible predisposing factor for RA in these subgroups. No accumulation of the +49
∗G
allele was found among patients, and this variant was not found to correlate with RA. Assaying the possible genotype variations,
the +49
∗G-CT60
∗G allelic combination was accumulated in seropositive RA-subtypes, and was associated with the risk of RA
(OR = 1.73, P = .001 for the whole RA-population). Although the +49
∗G allele did not mean a predisposition to RA alone, in
combination with CT60
∗G it, also conferred risk, suggesting that the +49A/G variant is associated with the risk of RA only in
certain haplotypes.
Copyright © 2010 Bernadett Farago et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
The cytotoxic T lymphocyte associated antigen (CTLA4)
is a well-known cosignalling molecule of the B7 receptor
immunoglobulin family. CTLA4 is expressed by CD4+,
CD8+, T and B lymphocytes, and is located on the surface
of the cell. Its expression and its density on the cell surface is
aﬀected by the activation of the T lymphocytes. Contrary to
CD28, which transmits a stimulatory signal to the T cells by
bindingtoB7-1orB7-2receptorsonantigenpresentingcells,
CTLA4isaninhibitoryfactorinT-cellactivatingsystems[1].
The CTLA4 gene polymorphisms are reportedly associ-
ated with a variety of T cell-mediated autoimmune diseases
such as type 1 diabetes mellitus [2, 3], systemic lupus ery-
thematosus, Hashimoto thyroiditis [4], Addison disease [5],
Grave’s disease [6–8], multiple sclerosis [9–11], and celiac
disease [12, 13]. Previous investigations on the association of
CTLA4 with RA [14–22] resulted in controversial outcomes.
Nistico et al. identiﬁed a +49A/G transition polymor-
phism of the leader sequence in exon 1, resulting in a
threonine to alanine change at position 17 of the amino
acid sequence [2]. In patients carrying the homozygous
GG genotype, the hydrophobic alanine is inserted into the
highly conservative sequence of the CTLA4 leader peptide.
This slight alteration of the leader peptide may aﬀect
the intracellular transport of the CTLA4 protein and its
availability on the cell surface [23]. As GG homozygotes
have fewer functionally active CTLA4 molecules on the cell
surface of the T lymphocytes, fewer B7-CTLA4 associations
can form, leading to a less eﬃcient CTLA4-mediated T cell
inhibition. As a consequence, a signiﬁcantly increased T cell
proliferation can be observed, compared to AA homozygotes
[24].
Another polymorphism, the CT60 (A6230G) allele in the
3 -UTR region, encodes either a protective A variant or a
predisposing G variant for autoimmune diseases [20]. The
G allele is associated with lower mRNA levels of the soluble
CTLA4isoform.Boththe+49A/GandtheCT60A/Gvariants
have been reported to confer risk for rheumatoid arthritis,
however, the results are controversial [14], some ﬁndings
aﬃrm the role of the SNPs in RA [15, 17, 19, 20], while
others could not reveal any association [16, 18, 21, 22]. The2 Autoimmune Diseases
aim of the present study was to examine the distribution of
these two SNPs in Hungarian RA patients separately and in
haplotype combinations.
2.MaterialsandMethods
A total of 428 well-characterised RA patients (102 males
and 326 females, mean age 54.9 ± 14.5 years), fulﬁlling the
diagnostic criteria of the American College of Rheumatology
[25] for rheumathoid arthritis were selected for the study.
However, 230 (98 males, 132 females, mean age 57.4 ± 16.1
years) clinically healthy individuals were carefully selected as
controls. None of the controls had any evidence or history
of any major metabolic disorder, and a special care was
taken to exclude patients with history of immunological
diseases. All control subjects ﬁt the criteria of RF- and
anti-CCP-seronegativity, as a basic criterion in our studies
[26–28]. All patients and controls were unrelated white
Caucasians. The DNA samples of each group were obtained
from a central pool governed by our department as part
of the Central National Biobank Network of Hungary
(http://www.biobank.hu). The RA samples were originally
collected in two medical centers, the University of Pecs
and University of Debrecen, all other samples are from
the University of Pecs. During the examination period,
guidelines of the local Ethics Committee and the 1975
Helsinki Declaration were followed.
The sera from nonhaemolyzed blood of each RA patient
was tested for the presence of RF and anti-CCP autoan-
tibodies using the Rheumatoid Factor Screen ORG522S
test by ORGENTEC Diagnostika GmbH (Mainz, Germany)
and the enzyme immunoassay of Euro-Diagnostica (Malm¨ o,
Sweden), respectively.
The +49A/G (GenBank rs231775) and the CT60 A/G
alleles (GenBank rs3087243) were examined by PCR RFLP
methods. For the ampliﬁcation of the target sequences,
the following primers were designed: 5 -CTTGAGGTT-
GTCTTTTCGAG-3  (forward) and 5 -TACTAAATACCT-
GGCGCTCT-3  (reverse) primers for +49G/A; and 5 -
ATCTGTGGTGGTCGTTTTCC-3  (forward) and 5 -TGG-
AAACCAAATGTGCTGAG-3  (reverse) primers for CT60.
The PCR ampliﬁcations were performed on MJ Research
PTC 200 thermal cyclers using the following conditions:
initial denaturation at 96◦Cf o r3m i n u t e sf o l l o w e db y3 5
cycles of denaturation at 96◦C for 45 seconds, annealing at
56◦C for 45 seconds, and extension at 72◦C for 45 seconds.
The ﬁnal extension was 10 minutes at 72◦C. The ampliﬁed
products were separated by agarose gel electrophoresis and
visualized by ethidium bromide staining.
The amplicons were then digested by restriction endonu-
cleases, +49A/G by Bse XI and CT60 by Mae II,a sr e c -
ommended by the manufacturer (Fermentas International
Inc., Burlington, Ont, Canada). Both methods designed
the amplicon contained an obligate restriction cleavage site
allowing us to monitor the eﬃcacy of the enyzme digestion.
The digestion fragments were separated by agarose gel
electrophoresisandvisualizedbyethidiumbromidestaining.
Statistical analysis was carried out using SPSS 11.5 for
Windows. We performed binary logistic regression analyses
and chi-square tests to reveal the possible associations
between the genetic and serological characteristics.
3. Results
In this Hungarian cohort, we chose to evaluate the allele
and genotype distribution of two variants of the CTLA4
gene, in relation to the development of rheumatoid arthritis.
The study comprised of 428 cases with RA and 230 healthy
controls. Upon isolation of genomic DNA from all patients
and controls, we performed genotyping using PCR-RFLP
methods speciﬁc for CTLA4 variants +49A/G and CT60.
Table 1 presents our ﬁndings, the allele frequencies of
the CT60 and +49A/G SNPs and of the +49∗G-CT60∗G
haplotype in the patients and controls. The CT60∗GG
genotype and the CT60∗G allele frequencies showed a
signiﬁcant increase in the RF- and/or anti-CCP-seropositive
RA populations, while no diﬀerence was observed in the
distribution of the +49A/G alleles compared to the healthy
controls. All alleles studied here were in Hardy-Weinberg
equilibrium in both the patient and control groups.
We also tested the frequencies of the possible haplotypic
combinations and their signiﬁcance. Comparing the preva-
lences of the +49∗A-CT60∗A, +49∗A-CT60∗G, +49∗G-
CT60∗A, and +49∗G-CT60∗G combinations, the +49∗G-
CT60∗G haplotype was found to accumulate in the entire
RA patient population, and further analysis revealed that
it was present at signiﬁcantly elevated frequencies in the
seropositive groups (Table 1).
The bivariate logistic regression analyses adjusted to age
and gender revealed that the CT60∗G and CT60∗GG vari-
ants represent independent risk for the development of RF-,
anti-CCP-seropositive and combined types of RA (Table 2).
Similarly, the simultaneous presence of the CT60∗Ga n d
+49∗G alleles showed an approximately 1.5-fold increase in
disease susceptibility considering the RF- and/or anti-CCP-
seropositive cases. The +49∗G variant alone was not found
to confer risk for the disease.
4. Discussion
In the present study we genotyped two functional SNPs of
the CTLA4 gene in RA patients and matched controls, pre-
viously characterized for RF- and anti-CCP-seropositivity.
The CT60∗GG genotype and the CT60∗G allele exhibited
an accumulation in the entire RA group when compared
with the healthy controls (33.9% versus 27.1% and 57.1%
versus 48.5%). However, subsequent analysis of the data
revealed a clear serology dependency: all seropositive groups
of patients showed a signiﬁcantly increased prevalence of the
CT60∗GG genotype and the CT60∗G allele compared to the
controls. On the other hand, no similar diﬀerences could be
establishedbetweentheseronegativepatientsandthecontrol
cases regarding the CT60∗GG genotype- and CT60∗Ga ll e l e -
distribution. This suggests that carrying the CT60∗G variant
does not mean predisposition for RF- and/or anti-CCP-
seronegative subtypes of RA; however, it might confer
susceptibility for RF- and/or anti-CCP-seropositive forms of
the disease.Autoimmune Diseases 3
Table 1: The distribution and frequencies of the CTLA4 CT60 and +49A/G genotypes and alleles, and the +49∗G-CT60∗G haplotype
stratiﬁed by RF- and anti-CCP-seropositivity in patients versus controls.
RA patients Control
RF anti-CCP RF + anti-CCP
Total Positive Negative Positive Negative Positive-positive Negative-negative Total
(n = 428) (n = 324) (n = 104) (n = 310) (n = 118) (n = 286) (n = 80) (n = 230)
CT60
AA (%) 84 (19.6)∗ 62 (19.1)∗ 22 (21.2) 59 (19.0)∗ 25 (21.2) 54 (18.9)∗ 17 (21.3) 64 (24.0)
GA (%) 199 (46.5) 143 (44.1) 56 (53.8) 131 (42.3) 68 (57.6) 122 (42.7) 47 (58.8) 109 (48.8)
GA+GG (%) 344 (80.4) 262 (80.9) 82 (78.8) 251 (81.0) 93 (78.8) 232 (81.1) 63 (78.8) 166 (78.4)
GG (%) 145 (33.9)∗ 119 (36.7)∗ 26 (25.0) 120 (38.7)∗ 25 (21.2) 110 (38.5)∗ 16 (20.0) 57 (27.1)
G (%) 489 (57.1)∗ 381 (58.8)∗ 108 (51.9) 371 (59.8)∗ 118 (50.0) 342 (59.8)∗ 79 (49.4) 223 (48.5)
+49A/G
AA (%) 160 (37.4) 122 (37.7) 38 (36.5) 112 (36.1) 48 (40.7) 104 (36.4) 30 (37.5) 98 (42.6)
GA (%) 201 (47.0) 151 (46.6) 50 (48.1) 147 (47.4) 54 (45.8) 135 (47.2) 38 (47.5) 97 (42.2)
GA+GG (%) 268 (62.6) 202 (62.3) 66 (63.5) 198 (63.9) 70 (59.3) 182 (63.6) 50 (62.5) 132 (57.4)
GG (%) 67 (15.7) 51 (15.7) 16 (15.4) 51 (16.5) 16 (13.6) 47 (16.4) 12 (15.0) 35 (15.2)
G (%) 335 (39.1) 253 (39.0) 82 (39.4) 249 (40.2) 86 (36.4) 229 (40.0) 62 (38.8) 167 (36.3)
+49∗G-CT60∗G 182 (21.3)∗ 147 (22.7)∗ 35 (16.8) 147 (23.7)∗ 35 (14.8) 134 (23.4)∗ 22 (13.8) 62 (13.5)
∗P< . 0 5i nt h ep r e v a l e n c eo ft h eA Aa n dG Gg e n o t y p e s ,t h eGa l l e l e ,o rt h e+ 4 9 ∗G-CT60∗G haplotype versus controls.
Table 2: The results of the binary logistic regression analyses considering the CT60∗GG genotype, the CT60∗G allele, and the +49∗G-
CT60∗G haplotype in RA patients stratiﬁed by RF- and anti-CCP-seropositivity versus controls.
RA Patients
RF anti-CCP RF + anti-CCP
Total Positive Negative Positive Negative Positive-
positive
Negative-
negative
CT60∗GG
OR (95%CI) 1.56
(1.09–2.23)
1.76
(1.21–2.56)
1.01
(0.59–1.73)
1.92
(1.32–2.79)
0.82
(0.48–1.39)
1.90
(1.29–2.78)
0.76
(0.41–1.42)
P .016 .003 .966 .001 .455 .001 .386
CT60∗G
OR (95%CI) 1.42
(1.13–1.78)
1.52
(1.20–1.93)
1.15
(0.83–1.60)
1.58
(1.24–2.02)
1.06
(0.78–1.46)
1.58
(1.23–2.03)
1.04
(0.72–1.49)
P .003 .001 .410 < .001 .145 < .001 .845
+49∗G-C T 6 0 ∗G
OR (95%CI) 1.73
(1.27–2.37)
1.88
(1.36–2.61)
1.30
(0.83–2.04)
2.00
(1.44–2.76)
1.12
(0.71–1.75)
1.96
(1.41–2.73)
1.02
(0.61–1.73)
P .001 <0 .001 .256 <0 .001 0.626 < .001 .931
In RF- and anti-CCP-seropositive subjects the CT60∗G
allele represented an approximately 1.5-fold risk for the
development of RA in our patient population. These results
are in agreement with previous ﬁndings [19], reporting
a slightly lower susceptibility (OR = 1.18, 95%CI: 1.07–
1.31, P = .006) in Caucasian patients with anti-CCP-
positive RA. Similarly, a Chinese cohort [29] demonstrated
a susceptibility of OR = 1.41 (95%CI: 1.10–1.82, P = .005),
considering the entire RA population with no regard to anti-
CCP seropositivity.
It has been reported that the CT60∗G variant is likely
associated with the RF-seropositive form of RA [19]. So far
no data has been published on samples seropositive, both
for RF and anti-CCP. Our examinations revealed a risk of
1.58 (95%CI: 1.23–2.03, P<. 001) in the double-seropositive
group, which is similar to that observed in the subgroups
characterizedbyseropositivityforeitherRForanti-CCP(OR
= 1.52, 95%CI: 1.20–1.93, P = .001; and OR = 1.58, 95%CI:
1.24–2.02, P<. 001, resp.).
Based on the relatively high ratio of patients with the
homozygous CT60∗GG genotype, we hypothesize that the
CT∗60G is a susceptibility factor for RA in the Hungarian
population. Furthermore, the CT60∗GG homozygous state
represents an approximately 2-fold risk for RA in the
seropositive subsets of samples, compared to the risk of
carrying the G allele in a heterozygous form. This may4 Autoimmune Diseases
suggest a gene dose dependency in inﬂuencing disease
susceptibility although the presence of two copies of the
CT60∗G variant does not mean an actual double risk,
compared to a single copy of the variant.
Contrarytoourﬁndingsandpreviousreports[19],some
other studies on a Caucasian patient population failed to
demonstrate any associations between the CT60∗G variant
and rheumatoid arthritis [22]. A likely explanation for
this controversy is that cohorts including relatively small
numberofsamplesmightfailtodetectstatisticallysigniﬁcant
diﬀerences, since the allele frequencies of the CT60 A and
G variants are similar to each other in the general popula-
tion. However, marginally signiﬁcant diﬀerences regarding
the susceptibility alleles may be detected in the patient
group. Furthermore, the odds ratios found are relatively
low (approximately OR = 1.5), therefore, it would not be
surprising if studies with smaller sample size could not
reveal any signiﬁcant correlation between the possible risk
alleles and the disease. Another explanation is that the above
controversy might be due to heterogeneity across study
populations, where a susceptibility allele identiﬁed in one
populationhasnodisease-associationinanotherpopulation.
Considering the +49A/G polymorphism, we could not
detect any signiﬁcant diﬀerences regarding the genotype and
allele distributions of the RA and control samples (Table 1).
Previous works [15–22] documented controversial outcomes
on the possible association between this variant and RA.
It is possible, that the +49A/G polymorphism does not
increase disease susceptibility alone, but together with other
predisposing factors, it increases the risk for developing RA,
as some studies [17, 30, 31] demonstrated an association
in HLA-DRB1∗04 patients, while others [16, 22] found no
association irrespective of the HLA-shared epitope status.
A study on Chinese patients [29] suggested that CT60 is a
possibleindependentcausalvariantinRA,andthattheeﬀect
of the +49∗G variant is dependent on the CT60∗Ga l l e l e ,
since when the +49∗G allele is combined with the CT60∗G
in a haplotype, their eﬀect is increased. We were not able
to replicate these ﬁndings in our study (data not shown),
although it is possible that the correlations found in Asian
populations do not stand for Caucasians.
Theexactmolecularbackgroundofhowthepredisposing
CT60∗G variant aﬀects CTLA4 function and thus T-cell
activation is not fully understood. A recent report [20]
indicated that the CT60 variant inﬂuences the splicing and
production of soluble CTLA4, and that the CT60∗Ga l l e l e
is associated with lower mRNA levels of the soluble CTLA4
isoform compared to the protective CT60∗A variant. A
smaller amount of functionally intact CTLA4 molecules will
hinder the T-cell-attenuation, as the interaction between
B7 receptor and CTLA4 is less eﬃcient. A defect of this
attenuating system may, therefore, be an important risk
factor in the development of RA. Contrary to this, a recent
study [32] could not support this hypothesis.
5. Conclusions
Although the molecular mechanisms through which the
CT60 variant of CTLA4 exerts its eﬀect in the development
of autoimmune diseases are yet to be clariﬁed, it should be
emphasized that the CTLA4 CT60∗G variant represents an
1.5-foldriskforthedevelopmentofRAintheHungariansets
of RF- and/or anti-CCP-seropositive rheumatoid arthritis
patients. Since a relatively small number of studies have been
conducted and controversial ﬁndings have been reported on
the role of the +49A/G and the CT60 genetic variants in the
development of RA, further investigations are required.
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